Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking.
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
Cocco, Eleonora;
2022-01-01
Abstract
Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
